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ABSTRACT
Immune tolerance describes specific unresponsiveness to antigens. In clinical situations such as graft-versus-host
disease it may be useful to capitalize on these pre-existing tolerance mechanisms to treat patients. Extracorporeal
photopheresis is a pheresis treatment whereby the approximately 5  109 leukocytes are treated with a photoac-
tivatable compound (8-methoxypsoralen) and UVA light, and immediately returned to the patient in a closed-loop,
patient-connected system. This therapy induces apoptosis of virtually all the treated leukocytes. There is growing
evidence that infusion of apoptotic cells may trigger certain tolerance mechanisms and, thus, be of therapeutic use
in graft-versus-host disease. These apoptotic cells are taken up by phagocytes (antigen-presenting cells) in the body
of the patient. Apoptotic cell engagement has been reported to induce several changes and functional activities in
the engulfing antigen-presenting cell. These antigen-presenting cells: (1) decrease production of proinflammatory
cytokines; (2) increase production of anti-inflammatory cytokines; (3) lower ability to stimulate T-cell responses; (4)
delete CD8 T effector cells; and (5) induce regulatory T cells. Any and all of these mechanisms could explain the
noted effect in graft-versus-host disease. It is still unclear which one or ones are truly responsible. Ongoing studies
in animals and human trials will ultimately unravel these details.
© 2006 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
The immune system is a collection of organs, cells,
nd molecules that work in concert to protect higher-
rder animals from a wide diversity of pathogens such
s bacteria, viruses, and parasites. A major component
n the initiation of immune responses is the require-
ent for “danger” signals derived from injured tissue
nd pathogens [1]. Ways of minimizing nonfunctional
r autoreactive activities also evolved to prevent de-
truction of healthy tissue by immune overreaction.
entral mechanisms of tolerance, which occur in the
one marrow and thymus, lead to deletion of autore-
ctive B and T cells whereas peripheral mechanisms of
olerance can lead to T-cell skewing (e.g. T-helper 1,
-helper 2), suppression (e.g. anti-inﬂammatory cy-
okines, regulatory cells), and peripheral deletion (e.g.
ctivation-induced cell death, veto cells). In the ma-
ority of cases these tolerance mechanisms help main-
ain balance between sufﬁcient immunity to ﬁght
athogens and overreaction to self (Figure 1). How- w
B&MTver, these mechanisms of tolerance are usually not
ufﬁcient to overcome complications caused by allo-
eneic hematopoietic stem cell transplantation.
Graft-versus-host disease (GVHD) is a serious
omplication of hematopoietic stem cell transplanta-
ion leading to signiﬁcant morbidity and mortality.
urrent treatment (e.g. steroids, immunosuppres-
ants, T-cell depletion) is based primarily on inhibi-
ion of the effector arm of the immune system re-
ponds believed to be responsible for the development
f GVHD. Although these therapies have decreased
he incidence and severity of GVHD, toxic side effects
ave limited their use. To expand the use of hemato-
oietic stem cell transplantation, less toxic and more
ffective therapies for GVHD need to be developed.
ecent reports of using tolerance-boosting mecha-
isms such as adding regulatory T cells or tolerogenic
ntigen-presenting cells (APCs) have produced prom-
sing results in animal models [2-5]. This brief review
ill discuss one such tolerance-inducing therapy: the
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8nfusion of apoptotic cells (ACs) generated by extra-
orporeal photopheresis (ECP).
XTRACORPOREAL PHOTOPHERESIS
Extracorporeal photopheresis has been used clin-
cally for almost 20 years as an approved therapy for
he palliative treatment of cutaneous T-cell lym-
homa (CTCL). ECP instruments reside in many
ajor academic institutions in Europe and North
merica. This therapy is an apheresis-based process
hereby approximately 5  109 autologous leukocytes
re treated with a photoactivatible compound, 8-me-
hoxypsoralen, followed by exposure to 1.5 J/cm2 of
ltraviolet A light and reinfused. This occurs in a
oint-of-care, patient-connected, sterile, closed-loop
ystem. As a result of ECPs demonstrated efﬁcacy and
afety proﬁle in CTCL, physicians applied ECP treat-
ent to a wide variety of diseases that respond to
mmunosuppression [6] including GVHD [7-9]. The
istory of ECPs development for CTCL is well doc-
mented [10]. During the last two decades several
echanisms have been proposed as the mode of action
f ECP. Unfortunately, none are completely satisfy-
ng from a scientiﬁc standpoint, especially in the ab-
ence of convincing data. From the beginning it was
lear that the therapeutic effect of ECP could not be
xplained solely by destruction of malignant cells, be-
ause only a small proportion of the circulating patho-
enic T cells are treated during an ECP treatment
ycle. This led to the hypothesis that a systemic and
peciﬁc immune-mediated antitumor activity may be
nvolved in the clinical activity of ECP [11]. The
igure 1. The immune system is a careful balance between priming
mmune responses. Traditional therapies act primarily via inhibition
dd clinical value by targeting the tolerance side of the immune b
raditional therapies.ossibility that ECP induces a generalized immuno- ruppression is unlikely because patients with CTCL
ndergoing long-term ECP therapy have not demon-
trated a higher risk of developing infections or ma-
ignancies [12] and respond normally to both novel
nd recall antigens [13]. This review summarizes the
ecent work concerning the mechanism of action of
C infusion.
MMUNE REGULATION BY ECP: AC CLEARANCE
ECP induces the cell death of most of the treated
eukocytes within 24 to 48 hours [14-16]. What is the
onsequence of infusing patients with a bolus of ACs?
It has been known since the time of Metchnicoff
hat cellular debris is removed from complex organ-
sms by phagocytes. Many cell types in the body can
emove apoptotic and cellular debris from tissues;
owever, the professional phagocyte, or APC, has a
igher capacity to do so. The recognition of ACs occurs
y a series of evolutionarily conserved, AC-associated
olecular-pattern receptors on APCs that recognize
nd bind corresponding AC-associated molecular pat-
erns found on ACs. These receptors recognize li-
ands such as phosphotidyl serine and oxidized lipids
ound on ACs. The full description of the receptor
ystems involved in AC clearance is beyond the scope
f this article and has been reviewed in detail [17,18].
he vast majority of ECP-treated cells are retained in
he spleen and liver after infusion where they are
resumably engulfed by APCs [14,19].
Multiple laboratories using a variety of methods
nd models both in vitro and in vivo have now re-
orted that AC clearance by APCs regulates immune
or function to ﬁght pathogens and tolerance to inhibit overzealous
effector arm of the immune response. Therapies such as ECP may
offering a novel way to treat disease and possibly synergize witheffect
of the
alance,esponses [17]. This immune modulation appears to
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Potential Mechanisms of Photopheresis
Bccur primarily by an alteration of APC function with
everal hallmarks of a tolerance-inducing APC. There
s confusion about the nature and phenotype of tolero-
enic APCs; however, functional characteristics in a
ariety of systems imply their existence, even if it is
ransient [20,21]. Clearance of ACs in a noninﬂam-
atory situation may be an important natural re-
inder of self and an ongoing peripheral tolerance
echanism [22,23]. APCs in the periphery take up
Cs and transfer them to draining lymph nodes.
hese tolerogenic APCs do not appropriately stimu-
ate T effector cells and may induce tolerance using
everal different mechanisms outlined below. Only in
he presence of a stimulatory milieu from the tissue
ill the phagocyte be altered to become immunogenic
nd stimulate T cells to ﬁght the pathogens. Although
ignals [1] that activate immune responses have been
ell deﬁned during the last decade, it has been as-
umed that the absence of such signals was simply a
efault leading to no immune response. It has recently
een suggested that ACs from normal tissues are one
echanism of active tolerance induction. The cells are
aken up by APCs and deliver autoantigens in an anti-
nﬂammatorymanner, ensuring self-tolerance [23]. Den-
ritic cells (DCs) may play an important role in this
olerance as they have all the appropriate receptors,
nd they are the only APC known to present AC
eptides by both HLA antigen class I and class II. The
resentation by HLA antigen class I is termed cross-
resentation because it “crosses” the classically de-
ned endogenous class I and exogenous class II com-
artments [24,25]. In a noninﬂammatory context this
resentation by APCs of self-antigens on HLA anti-
en class I to CD8 T cells is a mechanism to directly
olerize the CD8 T-cell compartment [26] and has
een demonstrated in apoptotic tolerance [27]. The
D8 T-cell tolerance mechanism may be particu-
arly relevant in GVHD, although other tolerance
echanisms, such as the generation of CD4 regula-
ory cells, could also lead to decrease of CD8 re-
ponses by indirect mechanisms.
To date, there are 5 mechanisms reported for the
ffect of ACs on the APCs responsible for their clear-
nce. Upon engagement of ACs, APCs will: (1) pro-
uce lower levels of proinﬂammatory cytokines secre-
ion; (2) secrete anti-inﬂammatory cytokines; (3) have
diminished effector T-cell stimulation capability; (4)
ossibly induce accelerated death of effector cells; and
able 1. Potential Mechanisms of Apoptotic Cell Induction of
olerance in Graft-versus-Host Disease
. Inhibition of proinflammatory cytokines
. Anti-inflammatory cytokine production
. Decreased stimulation of effector T cells
. Deletion of effector T cellst. Stimulation of regulatory cells
B&MT5) stimulate regulatory T-cell generation. These 5
echanisms (Table 1) may all, theoretically, be rele-
ant for the mechanism of action of ECP in GVHD.
tudies are now underway for animals and patients to
etermine which of these mechanisms may be playing
more relevant clinical role in GVHD.
nhibition of Proinflammatory Cytokines
The most well-studied phenomenon in the area of
C-mediated tolerance is the modulation of APC cy-
okine production in vitro. The decrease in proinﬂam-
atory cytokines such as interleukin (IL)-1, IL-6, tu-
or necrosis factor , and IL-12 is well documented
n several different APC cell types in both mice and
uman beings [28,29]. Neither the maturation state of
he DC [26] nor the type of AC [30-32] appear to
atter. Interestingly, the most dramatic decrease has
een reported for IL-12 [19,33]. Recently, Kim et al.
34] described a novel zinc ﬁnger nuclear factor,
amed GC binding protein, responsible for the down-
egulation of the p35 subunit of IL-12 after incubation
ith phosphotidyl serine liposomes. The central role
f IL-12 in the induction of immune responses is
ecoming increasingly apparent, and its absence dur-
ng T-cell stimulation by APCs may lead to regulatory
cells [35-38].
nti-Inflammatory Cytokine Production
In addition to the suppression of proinﬂammatory
ytokines, there is a well-described phenomenon of
ncreased anti-inﬂammatory cytokines secretion in-
luding transforming growth factor  [29,39] and IL-10
40]. These cytokines may be important in decreasing
mmune responses at inﬂammatory sites. At appropriate
oncentrations in secondary lymph node organs, these
ytokines inhibit stimulation of effector T cells and
rive regulatory T-cell generation [41-43].
ecreased Stimulation of Effector T Cells
Engagement of ACs by APCs decreases their abil-
ty to stimulate a functional effector immune re-
ponse [44]. There are several reported reasons for
his decrease in stimulatory activity. The APCs have
ecreased levels of costimulatory surface molecules,
uch as CD86, along with decreased levels of second-
ry cytokine signals such as IL-12 [33]. In addition,
Cs can inhibit maturation of DCs by CD36 ligation
45], and it has been suggested that immature DCs
ay not be as efﬁcient as mature DCs at stimulating
n immune response [46]. Finally, in the draining
ymph node, which harbors ACs, the local milieu of
nti-inﬂammatory molecules such as transforming
rowth factor , IL-10, prostaglandin E2, and plate-
et-activating factor may all act in a paracrine fashion
o diminish effector T-cell stimulation [29].
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1eletion of Effector T Cells
There are reports that delivery of ACs in vivo
eads to tolerance by deletion of the effector T cells.
he exact mechanism of this deletion is still not clear.
teinman et al. [22] suggested that the tolerogenic
PCs improperly stimulate the effector T cells so that
hey divide several times and then undergo an activa-
ion-induced cell death. Herndon et al. [47] recently
ublished results using a hapten-based model in which
hey found induction of anti-idiotypic cytotoxic lym-
hocytes that killed effector T cells in a manner rem-
niscent of veto cells.
timulation of Regulatory T Cells
Regulatory T cells comprise a heterogeneous group
f T lymphocytes, which actively inhibit immune re-
ponses [43,48,49]. They have been recognized to play
n important role in GVHD [5,50]. Thus, there is
reat excitement about the potential to develop regu-
atory T cell–based therapies.
One way to generate regulatory T cells in vivo is
y the infusion of ACs. There is evidence from both
nimal models and human treatments that AC infu-
ion, such as during ECP, induces regulatory T cells
14,16,51-53]. Maeda et al. [14] found that the im-
une modulation of ECP is mediated by regulatory
ells in a murine model of contact hypersensitivity.
eletion of either CD4 or CD25 from the transferred
opulation led to a loss of transferred protection sug-
esting the cells with protective activity express CD4
nd CD25. They also showed that the tolerance was
ntigen-speciﬁc, suggesting T-cell involvement. Klein-
lauss et al. [54] has recently reported in an animal
odel of GVHD that the induction of regulatory T
ells by AC infusion is through the generation of
ransforming growth factor  by macrophages in the
pleen of these animals. In human beings, Lamioni et
l. [16] showed that an up-regulation of CD4CD25
cells follows ECP treatment in solid organ trans-
lantation patients.
In recently published AC trafﬁcking experiments,
e were unable to ﬁnd ECP-treated cells in the ears of
apten-sensitized animals [14]. We presume that the
ode of action is in the secondary lymphoid organs
uch as the spleen. We surmise that, as with effector
esponses, antigen and APCs draining from the in-
ammatory site meet with T and B cells in secondary
ymph node organs. In the presence of ACs, an anti-
nﬂammatory environment is created, limiting the
timulation of effector T cells and possibly generating
egulatory T cells that may trafﬁc to the site of in-
ammation. Indeed, in the contact hypersensitivity
odel others have shown elevated levels of IL-10
essage, presumably derived from inﬁltrating regula-ory cells, after UVB treatment [55].
0CP IN GVHD
Most of the mechanistic studies cited above are in
itro or in a variety of different animal models and
iseases. It is not known which of the immune-mod-
lating mechanisms are most relevant to GVHD. On-
oing murine studies and clinical substudies in the
ontext of controlled clinical trials will hopefully ad-
ress this issue.
Many commercially available drugs control im-
une responses by suppression of the effector arm of
he immune system. However, their toxicity, the pro-
ound immunosuppression that they cause, and their
imited efﬁcacy call for more effective therapies. Tolero-
enic mechanisms of controlling disease are novel and
old great promise. Even more exciting is the possi-
ility of combining tolerance and effector suppression
herapies. Theoretically, combinations therapies may
ct in concert or even synergistically, to signiﬁcantly
mprove clinical outcomes by increasing the effective-
ess of therapy and by allowing a reduction in doses of
oxic drugs. Ongoing murine and human substudies
ill hopefully shed light on both the relevant mecha-
isms of immune tolerance in GVHD and mechanism
f action of ECP. This will in turn increase the effec-
ive use of ECP, and hopefully provide us with an-
ther therapeutic strategy to control GVHD.
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